Skip to main content
. Author manuscript; available in PMC: 2012 Apr 4.
Published in final edited form as: Mol Cancer Ther. 2010 Sep 3;9(11):3065–3073. doi: 10.1158/1535-7163.MCT-10-0623

Figure 5. Real-time microscopic tracking of dose-dependent inhibition of wild type Bcr-Abl by Imatinib (top) and Dasatinib (bottom).

Figure 5

CosE37 cells were transfected to co-express Picchu-CAAX and wild type Bcr-Abl as described and Imatinib (top) or Dasatinib (bottom) was applied at minute 9. Rate constants for each concentration of the kinase inhibitor are provided in the tables.